Literature DB >> 3262450

Chronic arsenic toxicity from drinking tubewell water in rural West Bengal.

D N Guha Mazumder, A K Chakraborty, A Ghose, J D Gupta, D P Chakraborty, S B Dey, N Chattopadhyay.   

Abstract

Hepatic damage caused by chronic exposure to arsenic has been frequently described. Here we report on 13 patients from West Bengal, India, who consumed large amounts of arsenic in drinking water. An epidemiological investigation of the study area showed evidence of chronic arsenical dermatosis and hepatomegaly in 62 (92.5%) of 67 members of families who drank contaminated water (arsenic level, 0.2-2 mg/l). In contrast, only six (6.25%) of 96 persons from the same area who drank safe water (arsenic level, <0.05 mg/l) had non-specific hepatomegaly, while none had skin lesions. Hepatomegaly occurred in all the 13 patients who were studied in detail, although five had splenomegaly. Biopsy of samples of liver from these patients revealed various degrees of fibrosis and expansion of the portal zone that resembled non-cirrhotic portal fibrosis (NCPF).

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3262450      PMCID: PMC2491171     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  10 in total

1.  Fowler's solution as an etiologic agent in cirrhosis.

Authors:  M FRANKLIN; W B BEAN; R C HARDIN
Journal:  Am J Med Sci       Date:  1950-06       Impact factor: 2.378

2.  Arsenical dermatosis from tubewell water in West Bengal.

Authors:  A K Chakraborty; K C Saha
Journal:  Indian J Med Res       Date:  1987-03       Impact factor: 2.375

3.  Noncirrhotic portal fibrosis.

Authors:  S K Sama; S Bhargava; N G Nath; J R Talwar; N C Nayak; B N Tandon; K L Wig
Journal:  Am J Med       Date:  1971-08       Impact factor: 4.965

4.  Obliterative portal venopathy of the liver. Associated with so-called idiopathic portal hypertension or tropical splenomegaly.

Authors:  N C Nayak; V Ramalingaswami
Journal:  Arch Pathol       Date:  1969-04

5.  Non-cirrhotic portal fibrosis with portal hypertension: a new syndrome. I. Clinical and function studies and results of operations.

Authors:  A K Basu; J Boyer; R Bhattacharya; K C Mallik; K P Sen Gupta
Journal:  Indian J Med Res       Date:  1967-04       Impact factor: 2.375

6.  Letter: Arsenic and non-cirrhotic portal hypertension.

Authors:  D V Datta
Journal:  Lancet       Date:  1976-02-21       Impact factor: 79.321

7.  Search for aetiological factors of non-cirrhotic portal fibrosis.

Authors:  D N Guha Mazumdar; A Ghose; N C Pal; J Mukherjee; B N Guharay
Journal:  Indian J Gastroenterol       Date:  1984-01

8.  Noncirrhotic presinusoidal portal hypertension associated with chronic arsenical intoxication.

Authors:  P M Huet; E Guillaume; J Cote; A Légaré; P Lavoie; A Viallet
Journal:  Gastroenterology       Date:  1975-05       Impact factor: 22.682

9.  Direct splenocaval shunt for selective decompression of portal hypertension in children.

Authors:  B N Guharay; P Sain; D Banerjee; D N Guha Majumdar; K P Sengupta; A K Basu
Journal:  Surgery       Date:  1980-03       Impact factor: 3.982

10.  Chronic oral arsenic intoxication as a possible aetiological factor in idiopathic portal hypertension (non-cirrhotic portal fibrosis) in India.

Authors:  D V Datta; S K Mitra; P N Chhuttani; R N Chakravarti
Journal:  Gut       Date:  1979-05       Impact factor: 23.059

  10 in total
  23 in total

1.  Arsenic in the environment--risks and management strategies.

Authors:  Ravi Naidu; Prosun Bhattacharya
Journal:  Environ Geochem Health       Date:  2009-01-16       Impact factor: 4.609

2.  Relations between exposure to arsenic, skin lesions, and glucosuria.

Authors:  M Rahman; M Tondel; I A Chowdhury; O Axelson
Journal:  Occup Environ Med       Date:  1999-04       Impact factor: 4.402

3.  Arsenic contamination in Kolkata metropolitan city: perspective of transportation of agricultural products from arsenic-endemic areas.

Authors:  Anirban Biswas; Shresthashree Swain; Nilanjana Roy Chowdhury; Madhurima Joardar; Antara Das; Meenakshi Mukherjee; Tarit Roychowdhury
Journal:  Environ Sci Pollut Res Int       Date:  2019-06-08       Impact factor: 4.223

4.  Regional alterations in the levels of brain biogenic amines, glutamate, GABA, and GAD activity due to chronic consumption of inorganic arsenic in developing and adult rats.

Authors:  T N Nagaraja; T Desiraju
Journal:  Bull Environ Contam Toxicol       Date:  1993-01       Impact factor: 2.151

5.  Oxidative stress and hepatic stellate cell activation are key events in arsenic induced liver fibrosis in mice.

Authors:  Subhadip Ghatak; Ayan Biswas; Gopal Krishna Dhali; Abhijit Chowdhury; James L Boyer; Amal Santra
Journal:  Toxicol Appl Pharmacol       Date:  2010-12-04       Impact factor: 4.219

Review 6.  Arsenic: opportunity for risk assessment.

Authors:  G Stöhrer
Journal:  Arch Toxicol       Date:  1991       Impact factor: 5.153

7.  Arsenic contamination of ground water and its health impact on population of district of nadia, west bengal, India.

Authors:  Debendra Nath Guha Mazumder; Aloke Ghosh; Kunal Kanti Majumdar; Nilima Ghosh; Chandan Saha; Rathindra Nath Guha Mazumder
Journal:  Indian J Community Med       Date:  2010-04

8.  Non-carcinogenic effects of inorganic arsenic.

Authors:  C O Abernathy; E V Ohanian
Journal:  Environ Geochem Health       Date:  1992-06       Impact factor: 4.609

9.  Use of serum vitamin B12 level as a marker to differentiate idiopathic noncirrhotic intrahepatic portal hypertension from cryptogenic cirrhosis.

Authors:  Ashish Goel; Banumathi Ramakrishna; Jayaprakash Muliyil; Kadiyala Madhu; K G Sajith; Uday Zachariah; Jeyamani Ramachandran; Shyamkumar N Keshava; R Selvakumar; George M Chandy; Elwyn Elias; C E Eapen
Journal:  Dig Dis Sci       Date:  2012-08-24       Impact factor: 3.199

10.  Environmental pollution and chronic arsenicosis in south Calcutta.

Authors:  D N Mazumder; J Das Gupta; A K Chakraborty; A Chatterjee; D Das; D Chakraborti
Journal:  Bull World Health Organ       Date:  1992       Impact factor: 9.408

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.